QuidelOrtho Corporation reports developments in in vitro diagnostics, including rapid testing, immunoassay and molecular testing, clinical chemistry, transfusion medicine and point-of-care diagnostic platforms. Company updates commonly address financial results, revenue trends, guidance, respiratory testing seasonality, international market conditions and portfolio activity across labs, cardiac, immunohematology and molecular diagnostics.
Recurring news also covers product and technology developments such as the LEX VELO System, a point-of-care molecular PCR platform with FDA 510(k) clearance and CLIA waived status for Flu A, Flu B and COVID-19 testing, as well as diagnostic education topics including syphilis screening and high-sensitivity troponin. Governance and management changes appear alongside business updates and investor conference participation.
Quidel Corporation (NASDAQ: QDEL) announced anticipated third-quarter revenues ranging from $475 million to $477 million, driven by increased demand for COVID-19 diagnostic products. The CEO highlighted the company’s role in enhancing testing accessibility and expects revenues to exceed $800 million in the last quarter of 2020. A virtual Investor Day is scheduled for November 12, 2020, where management will discuss significant business developments. Full financial results will be released in late October 2020.
Quidel Corporation (NASDAQ: QDEL) supports the U.S. Administration's initiative to provide COVID-19 rapid tests to school children. The company is ramping up production of its Sofia® rapid antigen tests, currently at two million tests per week, with plans to double this capacity. The aim is to reach a production run-rate of over 220 million tests per year by July 2021. Quidel's Sofia® tests are made in America, and the company emphasizes the importance of collaboration within the medical diagnostics industry during the pandemic.